Evidence map›Paper›PMID 34326998›Full record

ArticleJournal of global health2021

Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study.

Xianlong Zhou, Haifeng Hou, Luyu Yang, Guoyong Ding, Tao Wei, Cancan Li, Yuanyuan Heng, Ruining Liu, Min Ma, Zhuanzhuan Hu and 6 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Preparing for the next viral threat with broad-spectrum antivirals.The Journal of clinical investigation · 2023
    Review
  3. Review
  4. Article
  5. Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs.Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Xianlong ZhouEmergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Haifeng HouSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Luyu YangIntensive Care Unit, Wuhan Third Hospital, Wuhan, Hubei, China.
Guoyong DingSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Tao WeiSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Cancan LiSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Yuanyuan HengSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Ruining LiuEmergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Min MaIntensive Care Unit, Huazhong University of Science and Technology Union Jiangbei Hospital, Wuhan, Hubei, China.
Zhuanzhuan HuIntensive Care Unit, Huazhong University of Science and Technology Union Jiangbei Hospital, Wuhan, Hubei, China.
Lei HuangIntensive Care Unit, Huazhong University of Science and Technology Union Jiangbei Hospital, Wuhan, Hubei, China.
Xizhu XuSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Quan HuIntensive Care Unit, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China.
Yan ZhaoEmergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Weijia XingSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, Shandong, China.
Zhigang ZhaoEmergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Shandong First Medical University · CNHuazhong University of Science and Technology · CNWuhan University · CNZhongnan Hospital of Wuhan University · CNThe First People's Hospital of Jiangxia District · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe antiviral therapy has been considered as an ordinary intervention for COVID-19 patients. However, the effectiveness of antiviral therapy is uncertain. This study was designed to determine the association between the antiviral therapy and in-hospital mortality among severe COVID-19 patients.

methodsThis study enrolled severe COVID-19 patients admitted to four designated hospitals in Wuhan, China. The use of antiviral treatments, demographics, laboratory variables, co-morbidities, complications, and other treatments were compared between survival and fatal cases. The association between antiviral agents and in-hospital mortality were analyzed.

resultsIn total, 109 severe COVID-19 patients (mean age 65.43) were enrolled for analysis, among which, 61 (56.0%) patients were discharged alive, and 48 (44.0%) died during hospitalization. We found no association between lopinavir/ritonavir (LPV/r) treatment and the in-hospital mortality (odds ratio (OR) = 0.195, 95% confidence interval (CI) = 0.023-1.679). Besides, ribavirin (OR = 0.738, 95% CI = 0.344-1.582), oseltamivir (OR = 0.765, 95% CI = 0.349-1.636), and interferon-alpha (IFN-α) (OR = 0.371, 95% CI = 0.112-1.236) were not associated with the in-hospital mortality. However, arbidol monotherapy (OR = 5.027, 95% CI = 1.795-14.074) or the combination of arbidol and oseltamivir (OR = 5.900, 95% CI = 1.190-29.247) was associated with an increased in-hospital mortality. In addition, the multiple logistic regression identified a significant association between the use of arbidol and the in-hospital mortality (adjusted OR = 4.195, 95% CI = 1.221-14.408).

conclusionsOur findings indicated that LPV/r, IFN-α, ribavirin, or oseltamivir have no beneficial effects on the prognosis of severe COVID-19 patients, whereas the use of arbidol is associated with increased in-hospital mortality.

Indexed as

COVID-19COVID-19 Drug TreatmentHospital MortalityIndolesAgedChinaHumansRetrospective StudiesSeverity of Illness IndexSulfidesIndolesSulfidesumifenovir

Identifiers

PMID34326998
PMCPMC8284661
OpenAlexW3185415574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.